OraSure to acquire BioMedomics, expanding diagnostic portfolio

OraSure (OSUR) announced it signed a definitive agreement to acquire BioMedomics. The company said the transaction expands its diagnostic portfolio by adding SickleSCAN, a rapid, point-of-need test for sickle cell disease that is currently sold outside the U.S. OraSure stated it believes it can significantly expand the reach of SickleSCAN by leveraging its international sales channels and existing relationships with national health programs.